0

Nebulized Ipratropium Bromide Protects Against Tracheal and Bronchial Secretion During Bronchoscopy: A Randomized Controlled Trial

Faping Wang, He Zheng, Yanlin Zhang, Hui Zhu, Jingyu Shi, Yunxiao Luo, Xiang Zhang, Hui Mao, Felix J F Herth, Fengming Luo

Medicine (Baltimore). 2019 Nov;98(47):e17942.

PMID: 31764793

Abstract:

Background:
Anticholinergic administration prior to flexible bronchoscopy has been investigated, but studies have not yielded consistent results.
Methods:
Patients were randomized 1:1 to receive nebulized 4 ml ipratropium bromide (1 mg, n = 125) or placebo (n = 125) for 15 minutes as premedication, 20 to 40 minutes before bronchoscopy. Airway secretions, bleeding, patient discomfort, procedure time, and procedure-related adverse events were compared between the groups.
Results:
Nebulized ipratropium bromide prior to bronchoscopy could reduce airway secretions and patient discomfort (P = .02; P < .001, respectively), but not tracheobronchial bleeding or procedure time (P = .51, P = .36, respectively). Chest nodule or mass was the most common indication for performing bronchoscopy. The adverse events were higher in ipratropium bromide group, and hypertension was the most common complication.
Conclusion:
Nebulized ipratropium bromide prior to bronchoscopy is a more effective regimen that shows a practical benefit on the airway secretions and patient comfort, though these effects may not translate into any marked reduction in bleeding or of procedure time under general anesthesia. We suggest that routine nebulized ipratropium bromide premedication for bronchoscopy could be useful and beneficial.
Trial registration:
chictr.org.cn: ChiCTR1800016881.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
AP66985179-A Ipratropium bromide Ipratropium bromide 66985-17-9 Price
qrcode